Edgewise announces completion of EDG-7500 CIRRUS-HCM phase 2 parts B & C and favourable interim safety results from the ongoing part D study in hypertrophic cardiomyopathy ...
Hackensack Meridian JFK’s chief of cardiology explains how alcohol, salty foods, and holiday excess can lead to dangerous ...
Discover why Edgewise Therapeutics, Inc. is rated Buy amid strong trial data, unique HCM treatment, and major 2026 catalysts. Click for this EWTX update.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback